Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial

Blood (2025) 146 (25): 3050–3058.

https://doi.org/10.1182/blood.2025030084

Published: 2025

Includes: Supplemental data

Journal Articles

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL

Blood (2025) 146 (20): 2406–2416.

https://doi.org/10.1182/blood.2025028899

Published: 2025

Includes: Supplemental data

Journal Articles

Redefining early vs late progressive disease (PD) in chronic lymphocytic leukemia: A pooled analysis of fixed-duration therapies

Blood (2025) 146 (Supplement 1): 2107.

https://doi.org/10.1182/blood-2025-2107

Published: 2025

Journal Articles

Efficacy of 2nd-line treatment in CLL after venetoclax-based 1st-line treatment: Results from the GAIA/CLL13 trial

Blood (2025) 146 (Supplement 1): 795.

https://doi.org/10.1182/blood-2025-795

Published: 2025

Journal Articles

Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial

Blood (2025) 146 (Supplement 1): 101.

https://doi.org/10.1182/blood-2025-101

Published: 2025

Journal Articles

CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Meghan Thompson, Constantine Tam, Kenneth Wu, Sheel Patel, Motohisa Takai, Patrick Phuong, Shelonitda Rose, Mark-David Levin, Talha Munir, Paolo Ghia, John Seymour

Blood (2025) 146 (Supplement 1): 5691.

https://doi.org/10.1182/blood-2025-5691

Published: 2025

Journal Articles

Long term follow-up and results of retreatement after obinutuzumab-venetoclax in first-line CLL patients with coexisting conditions

Blood (2025) 146 (Supplement 1): 3897.

https://doi.org/10.1182/blood-2025-3897

Published: 2025

Journal Articles

Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age

Blood (2025) 146 (Supplement 1): 372.

https://doi.org/10.1182/blood-2025-372

Published: 2025

Journal Articles

Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial

Othman Al-Sawaf, Janina Stumpf, Can Zhang, Florian Simon, Francesc Bosch Albareda, Emadoldin Feyzi, Paolo Ghia, Michael Gregor, Arnon Kater, Vesa Lindström, Mattias Mattsson, Carsten Niemann, Philipp Staber, Tamar Tadmor, Patrick Thornton, Clemens-Martin Wendtner, Ann Janssens, Thomas Noesslinger, Jan-Paul Bohn, Caspar da Cunha-Bang, Christian Poulsen, Juha Ranti, Thomas Illmer, Bjoern Schoettker, Sebastian Böttcher, Tobias Gaska, Elisabeth Vandenberghe, Ruth Clifford, Ohad Benjamini, Annamaria Frustaci, Lydia Scarfo, Paolo Sportoletti, John Schreurs, Mark-David Levin, Hanneke van der Straaten, Marjolein van der Klift, Hoa Tran, Javier de la Serna, Javier Loscertales, Oscar Lindblad, Anna Bergendahl Sandstedt, Jeroen Goede, Michael Baumann, Anna Maria Fink, Kirsten Fischer, Matthias Ritgen, Karl-Anton Kreuzer, Christof Schneider, Eugen Tausch, Stephan Stilgenbauer, Sandra Robrecht, Barbara Eichhorst, Michael Hallek

Blood (2025) 146 (Supplement 1): 1.

https://doi.org/10.1182/blood-2025-1

Published: 2025

Journal Articles

CaDAnCe-302, a phase 3, open-label, randomized study of BGB-16673 compared with idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma previously exposed to both a BTK and BCL2 inhibitor

Constantine Tam, John Seymour, Jiayi Shen, Jan Michel, Maryam Sarraf Yazdy, Patrick Brown, Shelonitda Rose, Motohisa Takai, Meghan Thompson, Mark-David Levin, Talha Munir, Paolo Ghia, Jeff Sharman

Blood (2025) 146 (Supplement 1): 8245.

https://doi.org/10.1182/blood-2025-8245

Published: 2025

Journal Articles

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

Blood (2025) 145 (5): 543–546.

https://doi.org/10.1182/blood.2024025868

Published: 2025

Includes: Supplemental data

Journal Articles

Informative Censoring in Randomized First-Line Trials of Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 6799.

https://doi.org/10.1182/blood-2024-203673

Published: 2024

Journal Articles

In-Depth Immune and Metabolic Profiling of GAIA/CLL13 Patients to Uncover Treatment-Specific Changes to the T-Cell Compartment

Blood (2024) 144 (Supplement 1): 1846.

https://doi.org/10.1182/blood-2024-209692

Published: 2024

Journal Articles

Improved Innate Immune Function upon Preemptive Short-Term Acalabrutinib and Venetoclax in Newly Diagnosed CLL Patients with High Risk of Infections: Translational Findings from the Prevent-Acall Clinical Trial

Rebecca Svanberg Teglgaard, Rudi Agius, Caspar da Cunha-Bang, Tereza Faitova, Christian Brieghel, Hans Jakob Hartling, Hanne Vibeke Marquart, Robert Schou Pedersen, Christian Bjørn Poulsen, Mark-David Levin, Fransien De Boer, Koen de Heer, Rikke Kragh Lauridsen, Joanne Reekie, Anders Österborg, Jeanette Lundin, Magdalena Kättström, Sisse Rye Ostrowski, Carsten Utoft Niemann

Blood (2024) 144 (Supplement 1): 4609.

https://doi.org/10.1182/blood-2024-204985

Published: 2024

Journal Articles

Frailty Subgroups Determine Heterogeneous Outcomes in Elderly Patients with Newly-Diagnosed Multiple Myeloma - Long-Term Follow-up of the HOVON 143 Trial

Blood (2024) 144 (Supplement 1): 4739.

https://doi.org/10.1182/blood-2024-208754

Published: 2024

Journal Articles

Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial

Blood (2024) 144 (Supplement 1): 3238.

https://doi.org/10.1182/blood-2024-198917

Published: 2024

Journal Articles

Long-Term Follow-up from the Phase 2 ICON Study of Iberdomide Combined with Low-Dose Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IberCd)

Charlotte L.B.M. Korst, Wouter Plattel, Elizabeth de Kort, Alexandra Croockewit, Mark-David Levin, Matthijs Westerman, Okke De Weerdt, Inger S. Nijhof, Jurgen Wegman, Nina Smit, Christie P.M. Verkleij, Tuna Mutis, Marjolein van der Klift, Laurens Franssen, Kaz Groen, Ellen van der Spek, Wilfried Roeloffzen, Sonja Zweegman, Niels W.C.J. van de Donk

Blood (2024) 144 (Supplement 1): 3371.

https://doi.org/10.1182/blood-2024-200187

Published: 2024

Journal Articles

Telomere Length Associations with Characteristics and Outcome in Patients Treated with Venetoclax-Based First-Line Combinations in the GAIA/CLL13 Study

Blood (2024) 144 (Supplement 1): 4626.

https://doi.org/10.1182/blood-2024-204852

Published: 2024

Journal Articles

Improved Efficacy with Response- and MRD-Guided Ibrutinib-Obinutuzumab (IO) Intensification after Ibrutinib-Venetoclax (IV) in First Line Chronic Lymphocytic Leukemia (CLL) Patients: Primary Analysis of the HOVON 158/Next STEP Phase 2 Trial

Blood (2024) 144 (Supplement 1): 1013.

https://doi.org/10.1182/blood-2024-207452

Published: 2024

Journal Articles

Dynamics of Geriatric Impairments Are Associated with Risk of Treatment Discontinuation in Elderly Patients with Multiple Myeloma

Febe Smits, Kazem Nasserinejad, Mark-David Levin, Gert Jan Timmers, Esther G.M. De Waal, Josien C Regelink, Gerjo A. Velders, Matthijs Westerman, Nazik Durdu-Rayman, Suzanne Last-Koopmans, Roel JW van Kampen, Claudia A M Stege, Kaz Groen, Maarten R. Seefat, Monique C. Minnema, Pieter Sonneveld, Paula F Ypma, Niels W.C.J. van de Donk, Sonja Zweegman

Blood (2024) 144 (Supplement 1): 3330.

https://doi.org/10.1182/blood-2024-203477

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL

Redefining early vs late progressive disease (PD) in chronic lymphocytic leukemia: A pooled analysis of fixed-duration therapies

Efficacy of 2nd-line treatment in CLL after venetoclax-based 1st-line treatment: Results from the GAIA/CLL13 trial

Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial

CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Long term follow-up and results of retreatement after obinutuzumab-venetoclax in first-line CLL patients with coexisting conditions

Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age

Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial

CaDAnCe-302, a phase 3, open-label, randomized study of BGB-16673 compared with idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma previously exposed to both a BTK and BCL2 inhibitor

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

Informative Censoring in Randomized First-Line Trials of Chronic Lymphocytic Leukemia

In-Depth Immune and Metabolic Profiling of GAIA/CLL13 Patients to Uncover Treatment-Specific Changes to the T-Cell Compartment

Improved Innate Immune Function upon Preemptive Short-Term Acalabrutinib and Venetoclax in Newly Diagnosed CLL Patients with High Risk of Infections: Translational Findings from the Prevent-Acall Clinical Trial

Frailty Subgroups Determine Heterogeneous Outcomes in Elderly Patients with Newly-Diagnosed Multiple Myeloma - Long-Term Follow-up of the HOVON 143 Trial

Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial

Long-Term Follow-up from the Phase 2 ICON Study of Iberdomide Combined with Low-Dose Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IberCd)

Telomere Length Associations with Characteristics and Outcome in Patients Treated with Venetoclax-Based First-Line Combinations in the GAIA/CLL13 Study

Improved Efficacy with Response- and MRD-Guided Ibrutinib-Obinutuzumab (IO) Intensification after Ibrutinib-Venetoclax (IV) in First Line Chronic Lymphocytic Leukemia (CLL) Patients: Primary Analysis of the HOVON 158/Next STEP Phase 2 Trial

Dynamics of Geriatric Impairments Are Associated with Risk of Treatment Discontinuation in Elderly Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only